Molecular dysregulation of KAT6A and KAT6B has been observed in various tumor diseases, including solid tumors of the breast, lung, and ovary, as well as hematological tumors such as acute myeloid leukemia (AML) [29, 30, 31, 32, 33, 34, 35]. This evidence concerns the gene KAT6A and neoplasm.